Printer Friendly

Gene Security Network Introduces Single Cell Genetic Test for IVF Applications Powered By Parental Support(TM) Technology.

First Commercially Available Test to Quickly and Accurately Identify Abnormalities from a Single Embryonic Cell to Improve IVF Outcomes

REDWOOD CITY, Calif. -- Gene Security Network, Inc. (GSN) announced today the introduction of the All Chromosome Aneuploidy Screening test, powered by Parental Support([TM])bioinformatics. This is the first commercially available test to leverage bioinformatics to inform in vitro fertilization (IVF) transfer decisions by identifying potential abnormalities across all 24 chromosomes (aneuploidy) from a single embryonic cell. Test results are available within 24 hours and have an accuracy rate exceeding 99% for the cell tested.

Using Parental Support([TM]) technology, a single embryonic cell can be tested for a variety of molecular and cytogenetic diseases, including Down Syndrome as well as multiple genetic disorders such as muscular dystrophy, cystic fibrosis, and hereditary breast cancer. Parental Support([TM])technology uses genetic information from both the mother and the father - obtained via a simple cheek swab - as well as data from the Human Genome Project, to create an accurate reconstruction of the genome that can be used to provide highly accurate test results. This new method is far more accurate than existing methods which use technologies designed for large tissue samples - not for a single cell.

"While a wealth of data is emerging connecting genes with disease, doctors can rarely apply that information to help patients," said Matthew Rabinowitz, PhD, Chief Executive Officer of Gene Security Network, Inc. "We are excited that our technology can help couples worldwide who are faced with hereditary genetic diseases, infertility, or recurrent pregnancy failure."

"Since aneuploidy can result in IVF failure, this test helps identify embryos with the best chance for survival by screening all chromosomes with rapid turnaround to facilitate immediate decisions regarding which embryos to transfer," says Dr. David Smotrich, Medical Director of La Jolla IVF Center. "We've used GSN's All Chromosome Aneuploidy Screening and have been thrilled with the results."

GSN's All Chromosome Aneuploidy Screening test is currently being offered at the leading IVF centers in California including Huntington Reproductive Center, La Jolla IVF, and Stanford Fertility and Reproductive Medicine Center. GSN plans to roll out the test at other U.S. centers including Conceptions Reproductive Associates, Boston IVF, and NYU Fertility Center towards the end of 2008 and plans a nationwide rollout in the first half of 2009.

It is estimated that there were 150,000 IVF cycles performed in the U.S. in 2006, with another 650,000 cycles performed outside the U.S. It is estimated that approximately 6% of these cycles include preimplantation genetic diagnosis (embryo screening) including aneuploidy screening for the purpose of improving implantation rates, decreasing miscarriages, and preventing birth defects. As the ultimate goal of any IVF cycle is a healthy pregnancy, technologies that stand to improve IVF success rates, such as GSN's All Chromosome Aneuploidy Screening test, hold great promise for couples facing infertility.

GSN's Parental Support([TM]) technology can be applied to many genetic tests where only a small quantity of biological material is available for analysis. In 2009, GSN will offer IVF patients the ability to simultaneously test for multiple single gene disorders in addition to aneuploidy. GSN is also exploring applications of its technology beyond the IVF market.

About Gene Security Network

Gene Security Network is a privately held molecular diagnostics company that develops proprietary bioinformatics technologies for complex testing of small quantities of genetic material. GSN operates a CLIA-certified laboratory in Redwood City, California, providing testing services to guide doctors in screening embryos for chromosomal abnormalities and disease susceptibility during in vitro fertilization. GSN is funded by a highly respected group of venture investors including Claremont Creek Ventures and Sequoia Capital. For more information, please visit
COPYRIGHT 2008 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2008 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Nov 11, 2008
Previous Article:WildPackets Launches NetFlow Analyzer for OmniPeek.
Next Article:Pharmaceutical Contract Packaging Company Announces New Customer Service Department.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters